NASDAQ:BNTC Benitec Biopharma Q3 2025 Earnings Report $13.72 -0.29 (-2.07%) Closing price 04:00 PM EasternExtended Trading$13.68 -0.04 (-0.26%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Benitec Biopharma EPS ResultsActual EPS-$0.24Consensus EPS -$0.36Beat/MissBeat by +$0.12One Year Ago EPSN/ABenitec Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABenitec Biopharma Announcement DetailsQuarterQ3 2025Date5/14/2025TimeBefore Market OpensConference Call DateWednesday, May 14, 2025Conference Call Time4:00PM ETUpcoming EarningsBenitec Biopharma's Q1 2026 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Benitec Biopharma Earnings HeadlinesBenitec Biopharma Limited (NASDAQ:BNTC) Receives Average Recommendation of "Buy" from AnalystsOctober 1 at 2:12 AM | americanbankingnews.comBenitec Biopharma (NASDAQ:BNTC) Stock Rating Lowered by Wall Street ZenSeptember 28, 2025 | americanbankingnews.comFree: The Crypto Summit That Could Change Your LifeFed cuts unleash crypto's next wave The smart money is already moving. This is your chance to see their cards.October 2 at 2:00 AM | Crypto 101 Media (Ad)FY2026 EPS Forecast for Benitec Biopharma Lowered by AnalystSeptember 27, 2025 | americanbankingnews.comWhat is Leerink Partnrs' Estimate for BNTC Q1 Earnings?September 26, 2025 | americanbankingnews.comBenitec Biopharma's (BNTC) Market Outperform Rating Reiterated at JMP SecuritiesSeptember 26, 2025 | americanbankingnews.comSee More Benitec Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Benitec Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Benitec Biopharma and other key companies, straight to your email. Email Address About Benitec BiopharmaBenitec Biopharma (NASDAQ:BNTC) Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration. Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions. The hepatitis B program is advancing through preclinical studies to demonstrate potent and durable suppression of viral replication. In ocular disease, the company is exploring local delivery approaches to address wet age-related macular degeneration and other retinal disorders with RNAi-based constructs. Founded and headquartered in Australia, Benitec maintains research operations in both Melbourne and San Diego, California. Its international footprint supports collaboration with academic centers and contract development organizations to accelerate preclinical evaluation and future clinical trials. The company holds a portfolio of intellectual property covering its ddRNAi technology and related gene-silencing applications. Led by a management team with experience in gene therapy, molecular biology and drug development, Benitec Biopharma is focused on translating its platform into clinical-stage assets. The company continues to explore partnerships and licensing opportunities to broaden the scope of its gene-silencing pipeline and advance novel treatments toward regulatory approval.View Benitec Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
